Last reviewed · How we verify
Nosocomial pneumonia
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Tobi · Novartis
- Pipracil
Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death. - Ciprofloxacine · Poitiers University Hospital
- Vantobra · Pfizer
- Nebcin · University Hospital, Lille
- Piperacillin And Tazobactam · Pfizer
Piperacillin and tazobactam is an antibacterial drug combining a penicillin with a beta-lactamase inhibitor. - Zerbaxa · Cubist Pharms
Zerbaxa works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. - Arikayce Kit · Bristol-Myers Squibb
Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria. - Zosyn · Merck Sharp & Dohme B.V.
Zosyn works by blocking bacterial enzymes that break down antibiotics, allowing the antibiotics to kill bacteria more effectively. - Noroxin
- Floxin
- Cipro · Bayer AG
- Ofloxacine · Assistance Publique - Hôpitaux de Paris
Clinical guidelines
- FDA label — 1L
Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Combination therapy with an anti-pseudomonal β-lactam is recommended for Pseudomonas aeruginosa. - FDA label — 1L
Linezolid is indicated for the treatment of nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates) or Streptococcus pneumoniae. - FDA label — 1L
Levofloxacin is indicated for the treatment of nosocomial pneumonia due to specified bacteria. Combination therapy with an anti-pseudomonal β-lactam is recommended if Pseudomonas aeruginosa is a documented or presumptive pathogen.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Nosocomial pneumonia patent landscape — cliff calendar, originator estates, attackable patents
- Nosocomial pneumonia treatment landscape brief
- Nosocomial pneumonia treatment updates RSS
Frequently asked questions about Nosocomial pneumonia
What drugs treat Nosocomial pneumonia?
Tracked treatments include Ramycin, Tobi, Pipracil, Ciprofloxacine, Vantobra, Nebcin, Piperacillin And Tazobactam, Zerbaxa.
What is the treatment for Nosocomial pneumonia?
Standard treatment for Nosocomial pneumonia includes Ramycin, Tobi, Pipracil, Ciprofloxacine, Vantobra. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Nosocomial pneumonia?
FDA label publishes guidelines for Nosocomial pneumonia. 3 guideline references tracked.
Related
- Treatment landscape: Nosocomial pneumonia patent cliff · Nosocomial pneumonia CI report
- Treatment: Ramycin
- Treatment: Tobi · Novartis
- Treatment: Pipracil
- Treatment: Ciprofloxacine · Poitiers University Hospital
- Treatment: Vantobra · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing